Anavex Life Sciences Corp (AVXL)

[TTTav66]

The rationale for the 14 week duration is specifically related to the choice of using the CDR Continuity of Attention as the primary efficacy trial endpoint. In pretty much every company presentation for the past year, they have highlighted their belief that CogState IDN data from the Alz 2A trial should be predictive of what will be seen in the CDR measure.

See slides 23-25 here: https://www.anavex.com/wp-content/uploads/2020/02/Anavex-Presentation-February-2020.pdf